Tarsus Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TARS | OCUL | YDES | PVLA | DNTH | KOD | |
|---|---|---|---|---|---|---|
| Market cap | 3.48B | 1.66B | 448.36M | 1.94B | 4.56B | 6.24B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -206.7 | -5.1 | — | -17.9 | -17.7 | -28.9 |
| Price/book | 9.3 | 3.2 | 1.4 | 8.9 | 3.8 | 101.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +4.01% | −36.37% | −63.54% | +82.07% | +139.31% | +760.95% |
| Today | +1.69% | +0.27% | −5.94% | −3.16% | −0.97% | −0.61% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TARS news ›Reviewing Tarsus Pharmaceuticals (NASDAQ:TARS) and Novo Nordisk A/S (NYSE:NVO)
Posted by Michael Walen on Oct 10th, 2026 Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Novo Nordisk A/S (NYSE:NVO – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS). TD Cowen analyst Josh Jennings maintained a Buy rating on…
Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options
Tarsus Pharma (TARS) stock boosts XDEMVY sales guidance, delivers cash flow, and adds retina pipeline via acquisitions—see valuation, risks, and upside. - Tarsus Pharmaceuticals is transitioning from a single-product launch story to a…
Recent Analysts’ Ratings Updates for Tarsus Pharmaceuticals (TARS)
Posted by Michael Walen on Oct 2nd, 2026 Several brokerages have updated their recommendations and price targets on shares of Tarsus Pharmaceuticals (NASDAQ: TARS) in the last few weeks: Tarsus’ primary product is XDEMVY (lotilaner…
Contrasting Tarsus Pharmaceuticals (NASDAQ:TARS) & Astrazeneca (NYSE:AZN)
Posted by Danessa Lincoln on Sep 30th, 2026 Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Astrazeneca (NYSE:AZN – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
Tarsus to Present 11 Abstracts at Anaheim Eye Meeting
Yuika Yoshida has been a reporter covering healthcare, innovation and education at the Orange County Business Journal since 2023. Previous bylines include JapanUp! Magazine and Stu News Laguna. She received her bachelor's degree in…
Tarsus Group (LON:TAR) Posts Quarterly Earnings Results
Tarsus Group (LON:TAR – Get Free Report) announced its earnings results on Tuesday. The company reported GBX (1.69) EPS for the quarter, Digital Look Earnings reports. Tarsus Group Stock Down 3.4% Shares of Tarsus Group stock opened at GBX…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
themarketsdaily.com4
-
markets.businessinsider.com1
-
seekingalpha.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.